NP 202 - Armaron Biosciences

Drug Profile

NP 202 - Armaron Biosciences

Alternative Names: NP 202 - Neuprotect; NP-202 - NeuProtect

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NeuProtect
  • Developer Armaron Biosciences
  • Class Cardiovascular therapies; Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cardiovascular disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cardiovascular-disorders(Prevention, In volunteers) in Australia (PO, Capsule)
  • 26 Jun 2015 Armaron Biosciences plans a phase II trial in Myocardial infarction in Australia and New Zealand (ACTRN12615000609550)
  • 10 Jun 2014 Phase-I clinical trials in Cardiovascular disorders (Prevention, In volunteers) in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top